P1.01-101 Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.658
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib

Journal of Community and Supportive Oncology
OncologyHematology
2016English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-positive NSCLC Following Treatment With Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-35 Tumor Volume Analysis in ALK-Rearranged NSCLC Treated With Crizotinib: Identifying an Early Marker for Clinical Outcome

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy